IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) insider Bhavik Patel sold 1,855 shares of the company's stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
IQVIA Stock Down 2.2%
Shares of NYSE IQV opened at $228.18 on Wednesday. The company has a market capitalization of $37.56 billion, a price-to-earnings ratio of 28.31, a price-to-earnings-growth ratio of 1.97 and a beta of 1.18. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $251.36. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The business has a 50-day moving average of $197.37 and a two-hundred day moving average of $186.67.
IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to analysts' expectations of $4.30 billion. During the same period in the previous year, the company posted $2.81 EPS. The company's quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 11.61 earnings per share for the current fiscal year.
IQVIA declared that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company's management believes its stock is undervalued.
IQVIA News Summary
Here are the key news stories impacting IQVIA this week:
- Positive Sentiment: IQVIA reported second-quarter EPS of $3.15, above the $3.03 consensus estimate, while revenue of $4.37 billion also exceeded expectations. Revenue increased 8.7% year over year, and full-year 2026 EPS guidance was set at $12.80–$13.00. Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last
- Positive Sentiment: Record bookings and a sizable backlog point to continued demand for IQVIA’s clinical research, data and technology services. Investors are focused on the company’s ability to convert that backlog into revenue and earnings. The Backlog Tells the Real Story: Inside IQVIA’s Blowout Q2
- Positive Sentiment: IQVIA and Medera announced a collaboration aimed at advancing cardiac gene therapy and human-based drug discovery. The partnership could strengthen IQVIA’s position in specialized clinical development and data-driven research, though financial benefits are likely longer term. IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
- Neutral Sentiment: Analyst commentary remains broadly constructive, with a consensus “Moderate Buy” rating and an average price target of $241.88. However, analysts continue to emphasize execution and backlog conversion after the recent rally. 5 Insightful Analyst Questions From IQVIA’s Q2 Earnings Call
- Negative Sentiment: Insiders have recently sold shares, including W. Richard Staub’s sale of 5,500 shares for approximately $1.28 million and Bhavik Patel’s sale of 1,855 shares for about $436,000. These transactions reduce insider ownership and may weigh on sentiment, although they do not necessarily indicate deteriorating business conditions. Insider Selling: IQVIA Insider Sells $1,279,740 in Stock
- Negative Sentiment: IQVIA’s debt-to-equity ratio of 2.18 and current ratio of 0.71 highlight leverage and liquidity risks. The company’s proprietary data platform and clinical research growth remain attractive, but investors may require continued earnings execution to justify its valuation. Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?
Analyst Upgrades and Downgrades
IQV has been the topic of several recent research reports. Evercore reiterated an "outperform" rating and issued a $185.00 price objective on shares of IQVIA in a research report on Wednesday, April 8th. BMO Capital Markets lifted their price objective on IQVIA from $210.00 to $270.00 and gave the company an "outperform" rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, July 15th. Morgan Stanley reissued an "equal weight" rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Finally, Barclays reiterated an "overweight" rating on shares of IQVIA in a report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $241.88.
Check Out Our Latest Report on IQVIA
Hedge Funds Weigh In On IQVIA
A number of institutional investors and hedge funds have recently added to or reduced their stakes in IQV. Franklin Street Advisors Inc. NC acquired a new position in shares of IQVIA in the 4th quarter worth approximately $15,724,000. CWM LLC grew its position in IQVIA by 23.9% in the fourth quarter. CWM LLC now owns 55,830 shares of the medical research company's stock worth $12,585,000 after buying an additional 10,762 shares during the last quarter. Calamos Advisors LLC increased its holdings in shares of IQVIA by 268.1% in the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company's stock valued at $42,536,000 after buying an additional 137,441 shares in the last quarter. Assetmark Inc. lifted its position in shares of IQVIA by 33.6% during the 4th quarter. Assetmark Inc. now owns 172,625 shares of the medical research company's stock valued at $38,911,000 after acquiring an additional 43,436 shares during the last quarter. Finally, KBC Group NV lifted its position in shares of IQVIA by 68.2% during the 4th quarter. KBC Group NV now owns 779,128 shares of the medical research company's stock valued at $175,624,000 after acquiring an additional 315,883 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.
IQVIA Company Profile
(
Get Free Report)
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
